Impurity Qualification Thresholds in Pharma: A Practical Guide

Keywords

Impurity qualification thresholds, Pharmaceutical impurities, Impurity limits for APIs, Drug product impurities.

Impurity Qualification Thresholds: What Pharma Companies Must Know

Pharmaceutical impurities are unavoidable chemical substances in drug products. They may form during the synthesis of active pharmaceutical ingredients (APIs) or after storage of drug formulation for a longer time. However, their presence can affect the safety of the drug product and regulatory success. To avoid this scenario, the regulatory authorities recommend certain guidelines regarding impurity qualification thresholds. These thresholds can help in determining whether an impurity requires toxicological evaluation. Therefore, understanding these thresholds is essential.

This blog provides a structured and critical explanation of impurity qualification thresholds based on ICH guidelines.

Figure : Impurity Qualification Thresholds

Table of Contents

1. Introduction to Impurity Thresholds
2. Types of Impurity Thresholds
3. Qualification Threshold: Concept and Importance
4. ICH Q3A vs Q3B Thresholds
5. Dose-Based Threshold Calculations
6. Practical Examples
7. Critical Challenges in Industry
8. Best Practices for Pharma Companies
9. Flowchart for Identification and Qualification
10. Conclusion

1. Introduction to Impurity Thresholds

Impurities form during synthesis, storage, or formulation. Thus, the regulatory agencies require impurity identification and control. In this regard, the guidelines ICH Q3A (drug substances) and Q3B (drug products) define three key thresholds:

• Reporting threshold
• Identification threshold
• Qualification threshold

These thresholds increase sequentially. The regulatory expectations become stricter as impurity levels rise in drug products.

2. Types of Impurity Thresholds

2.1 Reporting Threshold

The reporting threshold is the minimum level at which an impurity must be reported.

• Typically starts at ~0.03–0.05%
• Ensures transparency in impurity profiling

2.2 Identification Threshold

At the identification threshold level, structural identification of the impurities becomes mandatory.

• Generally ≥0.05–0.10%, depending on dose
• Requires analytical characterization (LC-MS, NMR)

2.3 Qualification Threshold

The qualification threshold is the most critical part.

• Requires toxicological qualification
• Typically ≥0.15% or 1 mg/day (whichever is lower)

3. Qualification Threshold: Concept and Importance

Qualification means demonstrating that an impurity is safe at a given level.

• It involves toxicological studies or literature justification
• It ensures no additional risk beyond the API

Most importantly, the qualification thresholds are based on patient exposure, not just percentage levels. Therefore, two drugs with identical impurity percentages may have different regulatory outcomes.

Therefore, a key principle states that

• ≤1 mg/day exposure is generally considered safe for non-mutagenic impurities (ScienceDirect)

4. ICH Q3A vs Q3B Thresholds

4.1 ICH Q3A (Drug Substance)

ICH Q3A is applied to the drug substance or active drug. These guidelines focus on the following aspects:

• Impurities formed during synthesis
• Applies to APIs not previously registered (European Medicines Agency (EMA))

4.2 ICH Q3B (Drug Product)

The ICH Q3B is applicable to drug products or drug formulations. These guidelines focus on the following aspects:

• Degradation products
• Includes interactions with excipients and packaging (ICH Database)

Key Insight

Although both guidelines define thresholds, Q3B often involves stability-driven impurities, which are harder to predict.

5. Dose-Based Threshold Calculations

The threshold calculations depend strongly on the Maximum Daily Dose (MDD).

General Rule

• Low-dose drugs → lower thresholds
• High-dose drugs → stricter qualification

Impurity Qualification Threshold

The following table describes the criteria for the impurity qualification threshold.

Impurity limits are governed by both percentage and total daily exposure (mg/day).

![Table 1: Impurity Qualification Threshold Source : [Source: www.ema.europa.eu]

Table 1: Impurity Qualification Threshold [Source : [Source: www.ema.europa.eu]

In this table,

Maximum Daily Dose (MMD) is the amount of drug substance administered per day.

Higher reporting thresholds for the impurities should be scientifically justified.

Lower thresholds for the impurities can be appropriate if they are unusually toxic.

6. Practical Examples

Example 1 — API Impurity

Suppose a pharmaceutical company manufactures an antihypertensive API. It has the following criteria:

• Maximum Daily Dose (MDD): 500 mg/day
• Observed impurity level: 0.20%

The impurity exposure can be calculated as

• Impurity exposure = 500 mg × 0.20% = 1.0 mg/day

Interpretation

• ICH qualification threshold = 1 mg/day or 0.15% (whichever is lower)
• Here, impurity exposure = 1 mg/day (at the limit)
• However, percentage level (0.20%) exceeds 0.15%

👉 Conclusion: The impurity percentage level exceeds the qualification threshold; hence, toxicological data are required.

Example 2 — Drug Product Degradant

Suppose a paracetamol-based formulation undergoes stability testing. It has the following criteria:

• MDD: 2000 mg/day (2 g/day)
• Degradation impurity: 0.10%

The impurity exposure can be calculated as

• Impurity Exposure = 2000 mg × 0.10% = 2.0 mg/day

Interpretation

• For high-dose drugs (>2 g/day), stricter limits apply
• Even though the percentage is low, mg/day exposure is high

👉 Conclusion: Qualification is required

Critical Insight

Many formulators assume low percentage equals safety. However, regulators prioritize total daily exposure and not just impurity percentage values.

Example 3—Low Dose Oncology Drug

Suppose an oncology drug has the following criteria:

• Dose: 10 mg/day
• Impurity: 0.5%

The impurity exposure can be calculated as

• Impurity Exposure = 10 mg × 0.50% = 0.05 mg/day

👉 Here the percentage is already exceeding mg/day limit. Therefore, qualification is required

Critical Insight

Although the absolute exposure is low (0.05 mg/day), the impurity exceeds the percentage-based qualification threshold (0.15%). Therefore, qualification is required, with potential for case-by-case justification.

7. Critical Challenges in Industry

7.1 Late-Stage Impurity Detection

Impurities that are discovered during stability studies tend to delay the approval process. Therefore, it is recommended that impurity profiling at early stages be beneficial.

7.2 Unknown Impurities

Unidentified impurities above thresholds create regulatory risks. These scenarios strictly require

• Isolation of impurities
• Structural elucidation
• Risk assessment

7.3 Qualification Cost

Toxicological studies are expensive and time-consuming. However, skipping them leads to rejection. Therefore, it is mandatory to strictly follow the procedure.

7.4 Mutagenic Impurities

ICH Q3 guidelines do not fully address genotoxic risks. Instead, the ICH M7 guideline must be applied. The mutagenic impurities, such as nitrosamine impurities, may have a higher risk factor. Therefore, their identification and qualification are essential even at lower percentages.

8. Best Practices for Pharma Companies

8.1 Design a Robust Impurity Control Strategy

A robust control strategy could help to find out impurities. In this context, the researcher needs to consider the following aspects:

• Use forced degradation studies
• Predict degradation pathways

8.2 Apply Risk-Based Assessment

To understand the impurity profile, there are modern tools available that can help to design possible impurities. Also, it is possible to evaluate the toxicity of the impurities based on theoretical calculations. In this context, researchers may rely on the following tools:

• Combine structure alerts
• Use in silico toxicology tools

8.3 Align with ICH Early

The identification and characterization should be done at the early stages of the drug development process. This would be significantly impactful during the regulatory submissions of the drug product. And early compliance can prevent rework during submission.

8.4 Use Qualification by Comparison

"Qualification by comparison" means the following:

Demonstrating that an impurity is safe because it was already present at equal or higher levels in batches used in nonclinical or clinical studies.

Therefore, no additional toxicology study is required if prior exposure has already established safety.

9. Flowchart for Identification and Qualification

The following flowchart is useful for the identification and qualification of the impurities that are present in the drug substances or drug products. This must be followed during the early stages of the drug development process.

Figure 2: A flowchart for Identification and Qualification [Source: www.ema.europa.eu]

10. Conclusion

Impurity qualification thresholds are scientifically driven safety limits. Therefore, pharmaceutical companies must adopt a proactive approach towards the end.

In this context, understanding the relationship between dose, exposure, and toxicity is crucial. However, early identification and qualification reduce development risks significantly.

For chemistry graduates, mastering these concepts provides a strong foundation for careers in regulatory affairs, analytical development, and quality control.

References

1. ICH Q3A(R2) Guideline — Impurities in New Drug Substances Read guideline
2. ICH Q3B(R2) Guideline — Impurities in New Drug Products Read guideline
3. EMA Scientific Guideline on Q3B View document
4. ScienceDirect — Qualification Threshold Concept Access paper